PRESS RELEASE

28th September 2012

Aurobindo Pharma receives USFDA approval for Modafinil Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received approval from the US Food & Drug Administration to manufacture and market Modafinil Tablets USP 100mg and 200mg (ANDA 202566). The product is ready for launch.

Modafinil Tablets are the generic equivalent of Cephalon, Inc's Provigil® Tablets. Modafinil Tablets USP 100mg and 200mg and indicated in adults for treatment of narcolepsy, shift work sleep disorders and excessive daytime sleepiness associated with obstructive sleep apnea. The product has a market size of approximately US$ 1.2 Billion for the twelve months ending March 2012 according to IMS.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India

Aurobindo now has a total of 160 ANDA approvals (135 Final approvals including 1 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:
Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com